Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Methacetin · 1 trial · 5 indications
MBT baseline measure will be measured within a week before the anticipated HVPG procedure, but not on the same day. The HVPG will be measured approximately 30 minutes after i.v. propanolol is given and the MBT will be performed approximately one hour later.
MBT baseline measure will be measured within a week before the anticipated HVPG procedure, but not on the same day. The HVPG will be measured approximately 30 minutes after i.v. propanolol is given and the MBT will be performed approximately one hour later.
The MBT will be performed on subjects again after 60 days of oral beta blocker treatment and its results will be compared to previous MBT values.
| Arm | Type | Description |
|---|---|---|
| Methacetin (for BT) before / after Propanolol treatment. | EXPERIMENTAL | The methacetin breath test (MBT) will be performed before and after (within 2 hours) injection of Propanolol (BB) dose and once again after 60 days of oral administration of Propanolol. |
| Name | Type | Description |
|---|---|---|
| Methacetin (with Breath testing device) | DEVICE | The methacetin is enriched with carbon 13, a stable non- radioactive isotope, and has been found to be safe in hundreds of studies. The material is very similar to acetominophen. 75 milligrams (mm) of this material pre- dissolved in water are used. This material undergoes rapid metabolism by the liver. |
Inclusion Criteria: -\> 18 years old (M/F) -Diagnosis of cirrhosis: i. By liver biopsy ii. Or strong suspicion of cirrhosis by accepted criteria for the clinical diagnosis of cirrhosis (e.g. peripheral edema or varices, palpable hard left lobe of the liver, small right lobe span or palpable spleno...
Top 20 of 23 competitors
Methacetin is an investigational drug being studied for use in chronic liver disease, including cirrhosis, esophageal varices, portal hypertension, and bleeding. It is currently in Phase 1 clinical development.
Methacetin is being developed by Meridian Bioscience Inc, a company traded under the ticker VIVO.
Methacetin is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA.
Methacetin has one completed clinical trial, NCT01851252, titled 'MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy.' The trial enrolled 19 participants with chronic liver disease and related conditions in Israel.
Methacetin is also referred to as MBT, as indicated by the clinical trial title 'MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy.'